<p>Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that:</p>

<ul>
	<li>have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,</li>
	<li>are metastatic or where surgical resection is likely to result in severe morbidity, and</li>
	<li>have no satisfactory alternative treatments or that have progressed following treatment.</li>
</ul>